International Assets Investment Management LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1,105.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,000 shares of the medical research company’s stock after buying an additional 42,185 shares during the period. International Assets Investment Management LLC’s holdings in Amgen were worth $19,389,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also made changes to their positions in the company. CHICAGO TRUST Co NA grew its holdings in shares of Amgen by 5.7% during the 3rd quarter. CHICAGO TRUST Co NA now owns 3,041 shares of the medical research company’s stock worth $1,282,000 after purchasing an additional 163 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in shares of Amgen by 6.1% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 85,905 shares of the medical research company’s stock worth $36,210,000 after purchasing an additional 4,920 shares during the last quarter. Partners Wealth Management LLC acquired a new stake in shares of Amgen during the 3rd quarter worth about $328,000. Soltis Investment Advisors LLC increased its position in shares of Amgen by 8.8% during the 3rd quarter. Soltis Investment Advisors LLC now owns 31,750 shares of the medical research company’s stock worth $13,383,000 after purchasing an additional 2,578 shares during the last quarter. Finally, Choreo LLC raised its holdings in Amgen by 1.5% in the 3rd quarter. Choreo LLC now owns 18,598 shares of the medical research company’s stock valued at $7,839,000 after buying an additional 278 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.
Analysts Set New Price Targets
A number of research analysts have commented on AMGN shares. BMO Capital Markets decreased their target price on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a research report on Monday, October 12th. Citigroup increased their target price on shares of Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Scotiabank lifted their price target on shares of Amgen from $450.00 to $500.00 and gave the company an “outperform” rating in a research report on Monday, September 28th. Robert W. Baird boosted their price target on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, October 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Amgen has an average rating of “Hold” and an average target price of $389.71.
Read Our Latest Report on Amgen
Amgen News Summary
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
- Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
- Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
- Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
- Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
- Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview
Insider Buying and Selling
In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by company insiders.
Amgen Stock Up 1.1%
Shares of NASDAQ:AMGN opened at $466.01 on Friday. The firm has a market capitalization of $251.94 billion, a PE ratio of 28.96, a price-to-earnings-growth ratio of 3.37 and a beta of 0.41. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $475.65. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The firm’s 50-day moving average is $419.96 and its two-hundred day moving average is $374.79.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same quarter last year, the firm posted $6.02 earnings per share. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts predict that Amgen Inc. will post 22.96 EPS for the current year.
Amgen Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is presently 62.65%.
About Amgen
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.
Founded in 1980, Amgen is headquartered in Thousand Oaks, California.
Featured Stories
- Five stocks we like better than Amgen
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
